With 15 new gene and cell-based therapies in late-stage testing, the time is now to consider a critical strategic question: is there a pricing model for these budget-busting treatments that works in both safeguarding returns to innovators and providing access to patients at a price society is willing to pay? An analysis by ZS Associates looks at the options for biopharma going forward.